Novartis

Novartis, a pharmaceutical preparation manufacturer headquartered in Switzerland (CH), has reported its carbon emissions across various scopes. In 2025, the company's total reported emissions were approximately 4.38 billion kg CO2e. This figure comprises Scope 1 emissions of around 192.3 million kg CO2e and Scope 2 emissions of approximately 14.9 million kg CO2e (market-based). Scope 3 emissions constituted the largest portion, amounting to approximately 4.17 billion kg CO2e, with purchased goods and services being a significant contributor.

In 2024, Novartis's total emissions were approximately 4.52 billion kg CO2e, with Scope 1 emissions at about 210.6 million kg CO2e, Scope 2 emissions at roughly 29.8 million kg CO2e (market-based), and Scope 3 emissions at approximately 4.28 billion kg CO2e.

The company has set ambitious climate targets. Novartis is committed to achieving carbon neutrality in its own operations (Scope 1 and 2) by 2025. Furthermore, the company aims for net-zero greenhouse gas emissions across its value chain by 2040. As part of its near-term targets, Novartis plans to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2030 from a 2022 base year, and absolute Scope 3 GHG emissions by 42% within the same timeframe. In the long term, Novartis aims to maintain a minimum of 90% absolute Scope 1 and 2 emissions reductions from 2030 through 2040 and reduce absolute Scope 3 GHG emissions by 90% by 2040, both from a 2022 base year.

Novartis's climate commitments are aligned with Science Based Targets initiative (SBTi) standards, indicating a commitment to emissions reductions consistent with limiting global temperature increase to 1.5°C. The company has also signed the Climate Pledge, further demonstrating its dedication to addressing climate change.